RZLT
Rezolute Inc
NASDAQ: RZLT · HEALTHCARE · BIOTECHNOLOGY
$4.70
-4.47% today
Updated 2026-07-29
Market cap
$443.91M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.85
Dividend yield
—
52W range
$1 – $11
Volume
2.0M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C8.5
Quality
A3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
3.8
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$7.67
+63.19%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy6 Buy3 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 3.75 — safe zone
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-13.73M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-41.06M | $-51.79M | $-68.46M | $-74.41M | $-16.17M |
| EPS | — | — | — | — | $-0.85 |
| Free cash flow | $-39.77M | $-44.63M | $-57.37M | $-69.08M | $-13.73M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-30 | EVANS, DARON | Buy | 10,000 | $2.85 |
| 2026-03-02 | ROBERTS, BRIAN KENNETH | Sale | 11,439 | $2.99 |
| 2026-03-02 | EVANS, DARON | Sale | 11,438 | $2.99 |
Peer comparison
Smart narrative
Rezolute Inc trades at $4.70. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 3.75, it sits in the safe zone.
Frequently asked questions
What is Rezolute Inc's stock price?
Rezolute Inc (RZLT) trades at $4.70.
Is Rezolute Inc overvalued?
Rezolute Inc carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Rezolute Inc (RZLT)?
The 12-month analyst consensus target is $7.67, about 63.2% above the current $4.70. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Rezolute Inc's Altman Z-Score is 3.75, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-69.74%
Beta0.55
50D MA$4.16
200D MA$4.91
Shares out0.10B
Float0.07B
Short ratio—
Avg volume2.0M
Performance
1 week-2.95%
1 month-1.98%
3 months+60.91%
YTD+109.32%
1 year—
3 years—
5 years—